Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05136677
Study type Interventional
Source Bristol-Myers Squibb
Contact BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone 855-907-3286
Email Clinical.Trials@bms.com
Status Recruiting
Phase Phase 2
Start date January 25, 2022
Completion date October 8, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT06057935 - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Phase 2
Completed NCT02519049 - 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Terminated NCT02357147 - Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Phase 2
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Completed NCT02303899 - Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma Phase 2
Recruiting NCT05380713 - ......SMARTEST Trial...... Phase 2
Recruiting NCT05568680 - SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma Phase 1
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT06051695 - A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression Phase 1/Phase 2
Active, not recruiting NCT03502746 - Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Phase 2
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Not yet recruiting NCT06251310 - SW-682 in Advanced Solid Tumors Phase 1
Recruiting NCT05944237 - HTL0039732 in Participants With Advanced Solid Tumours Phase 1/Phase 2
Active, not recruiting NCT05455424 - Niraparib Efficacy in Patient With Unresectable Mesothelioma Phase 2
Recruiting NCT05324436 - A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Active, not recruiting NCT03654833 - Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Phase 2
Not yet recruiting NCT05698238 - Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours Phase 1